Feasibility and benefits of a structured prehabilitation programme prior to autologous stem cell transplantation (ASCT) in patients with myeloma; a prospective feasibility study

[1]  J. Snowden,et al.  Guidelines for screening and management of late and long‐term consequences of myeloma and its treatment , 2017, British journal of haematology.

[2]  Daniel Hind,et al.  Recruitment and retention of participants in randomised controlled trials: a review of trials funded and published by the United Kingdom Health Technology Assessment Programme , 2017, BMJ Open.

[3]  R. Siegert,et al.  Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta‐analysis , 2016, European journal of haematology.

[4]  M. Drayson,et al.  The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. , 2016, The Lancet. Haematology.

[5]  Richard W. Bohannon,et al.  Minimal clinically important difference for change in 6-minute walk test distance of adults with pathology: a systematic review , 2016 .

[6]  Deborah A Fitzsimmons,et al.  Moving towards an enhanced community palliative support service (EnComPaSS): protocol for a mixed method study , 2015, BMC Palliative Care.

[7]  J. Snowden,et al.  Living with advanced but stable multiple myeloma: a study of the symptom burden and cumulative effects of disease and intensive (hematopoietic stem cell transplant-based) treatment on health-related quality of life. , 2013, Journal of pain and symptom management.

[8]  J. Silver,et al.  Cancer prehabilitation: an opportunity to decrease treatment-related morbidity, increase cancer treatment options, and improve physical and psychological health outcomes. , 2013, American journal of physical medicine & rehabilitation.

[9]  R. Newton,et al.  A systematic review of pre-surgical exercise intervention studies with cancer patients. , 2013, Surgical oncology.

[10]  A. Holland,et al.  The return of the minimum clinically important difference for 6-minute-walk distance in chronic obstructive pulmonary disease. , 2013, American journal of respiratory and critical care medicine.

[11]  L Vogt,et al.  Validity of the Six-Minute Walk Test in Cancer Patients , 2013, International Journal of Sports Medicine.

[12]  R. Stephens,et al.  A mixed exercise training programme is feasible and safe and may improve quality of life and muscle strength in multiple myeloma survivors , 2013, BMC Cancer.

[13]  K. Courneya,et al.  Perceived benefits and barriers to exercise for recently treated patients with multiple myeloma: a qualitative study , 2013, BMC Cancer.

[14]  J. Snowden,et al.  Guidelines for supportive care in multiple myeloma 2011 , 2011, British journal of haematology.

[15]  J. Casillas,et al.  DETERMINING THE MINIMAL CLINICALLY IMPORTANT 1 DIFFERENCE FOR THE SIX-MINUTE WALK TEST AND THE 2002 METER FAST WALK TEST DURING CARDIAC REHABILITATION 3 PROGRAM IN CORONARY ARTERY DISEASE PATIENTS AFTER 4 ACUTE CORONARY SYNDROME , 2017 .

[16]  M. Campbell,et al.  What is a pilot or feasibility study? A review of current practice and editorial policy , 2010, BMC medical research methodology.

[17]  M. Groenvold,et al.  Health related quality of life in a nationally representative sample of haematological patients , 2009, European journal of haematology.

[18]  Karl Swedberg,et al.  Six minute walk test. , 2005, European heart journal.

[19]  K. Richards,et al.  Feasibility of Exercise During Treatment for Multiple Myeloma , 2003, Cancer nursing.

[20]  B Kirshner,et al.  A methodological framework for assessing health indices. , 1985, Journal of chronic diseases.

[21]  M. Karvonen,et al.  The effects of training on heart rate; a longitudinal study. , 1957, Annales medicinae experimentalis et biologiae Fenniae.